Chinese General Practice ›› 2025, Vol. 28 ›› Issue (15): 1862-1870.DOI: 10.12114/j.issn.1007-9572.2024.0496
• Original Research • Previous Articles Next Articles
Received:
2024-10-08
Revised:
2025-01-09
Published:
2025-05-20
Online:
2025-03-21
Contact:
FAN Shiming
通讯作者:
樊世明
作者简介:
作者贡献:
张柠负责研究的实施,撰写论文;任明负责提出主要研究目标,构思设计研究;沈有录、马艳梅、窦小红、普措、鲁星琴、薛睿、王福彦、林莹、张吉辉、田辉珍、韩萍、韩玉娟、韩淑萍、刘青灵负责数据的收集与整理;卢天龙、芦永良、鄂维建负责试验设计验证与质控;黄强进行论文的修订;樊世明负责文章的质量控制与审查,对文章整体负责,监督管理。
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2024.0496
组别 | 例数 | 年龄(岁) | 性别(男/女) | BMI (kg/m2) | 吸烟史[例(%)] | 饮酒史[例(%)] | 服药史[例(%)] | 高血压家族史[例(%)] | 民族[例(%)] | |
---|---|---|---|---|---|---|---|---|---|---|
藏族 | 汉族 | |||||||||
高海拔高血压组 | 60 | 60.1±14.3 | 24/36 | 25.7±3.9 | 15(25.0) | 17(28.3) | 19(31.7) | 12(20.0) | 25(41.7) | 35(58.3) |
高海拔健康组 | 30 | 59.7±15.5 | 13/17 | 22.5±2.7 | 8(26.7) | 3(10.0) | 0 | 2(6.7) | 13(43.3) | 17(56.7) |
低海拔高血压组 | 60 | 55.7±11.1 | 16/44 | 25.1±2.5 | 25(41.7) | 11(18.3) | 12(20.0) | 9(15.0) | 33(55.0) | 27(45.0) |
低海拔健康组 | 30 | 51.7±11.9 | 12/18 | 24.7±4.3 | 6(20.0) | 4(13.3) | 0 | 1(3.3) | 12(40.0) | 18(60.0) |
F(χ2)值 | 3.339 | 3.588a | 5.061 | 6.190a | 5.498a | 2.131a | 6.202a | 2.929a | ||
P值 | 0.243 | 0.310 | 0.134 | 0.103 | 0.139 | 0.144 | 0.102 | 0.403 |
Table 1 Comparison of basic characteristics of participants
组别 | 例数 | 年龄(岁) | 性别(男/女) | BMI (kg/m2) | 吸烟史[例(%)] | 饮酒史[例(%)] | 服药史[例(%)] | 高血压家族史[例(%)] | 民族[例(%)] | |
---|---|---|---|---|---|---|---|---|---|---|
藏族 | 汉族 | |||||||||
高海拔高血压组 | 60 | 60.1±14.3 | 24/36 | 25.7±3.9 | 15(25.0) | 17(28.3) | 19(31.7) | 12(20.0) | 25(41.7) | 35(58.3) |
高海拔健康组 | 30 | 59.7±15.5 | 13/17 | 22.5±2.7 | 8(26.7) | 3(10.0) | 0 | 2(6.7) | 13(43.3) | 17(56.7) |
低海拔高血压组 | 60 | 55.7±11.1 | 16/44 | 25.1±2.5 | 25(41.7) | 11(18.3) | 12(20.0) | 9(15.0) | 33(55.0) | 27(45.0) |
低海拔健康组 | 30 | 51.7±11.9 | 12/18 | 24.7±4.3 | 6(20.0) | 4(13.3) | 0 | 1(3.3) | 12(40.0) | 18(60.0) |
F(χ2)值 | 3.339 | 3.588a | 5.061 | 6.190a | 5.498a | 2.131a | 6.202a | 2.929a | ||
P值 | 0.243 | 0.310 | 0.134 | 0.103 | 0.139 | 0.144 | 0.102 | 0.403 |
组别 | 例数 | Hcy(μmol/L) | SBP(mmHg) | DBP(mmHg) | GSSG(U/L) | NO(g/mol) | SOD(ng/mL) |
---|---|---|---|---|---|---|---|
高海拔高血压组 | 60 | 15.72±2.32ab | 171±14ab | 109±10ab | 9.73±3.97ab | 17.31±2.22ab | 1.18±0.52ab |
高海拔健康组 | 30 | 12.44±2.61 | 125±2c | 87±1c | 1.37±0.67c | 22.74±2.96 | 2.13±0.49c |
低海拔高血压组 | 60 | 12.17±3.17a | 158±8a | 105±2a | 7.88±3.90a | 24.64±2.96 | 1.87±0.59a |
低海拔健康组 | 30 | 11.71±3.19 | 122±9 | 84±2 | 0.79±0.37 | 22.17±4.27 | 2.43±0.69 |
F值 | 8.710 | 7.866 | 11.508 | 57.718 | 62.731 | 39.394 | |
P值 | <0.001 | 0.006 | <0.001 | <0.001 | <0.001 | <0.001 |
Table 2 Comparison of blood pressure and laboratory test results in participants
组别 | 例数 | Hcy(μmol/L) | SBP(mmHg) | DBP(mmHg) | GSSG(U/L) | NO(g/mol) | SOD(ng/mL) |
---|---|---|---|---|---|---|---|
高海拔高血压组 | 60 | 15.72±2.32ab | 171±14ab | 109±10ab | 9.73±3.97ab | 17.31±2.22ab | 1.18±0.52ab |
高海拔健康组 | 30 | 12.44±2.61 | 125±2c | 87±1c | 1.37±0.67c | 22.74±2.96 | 2.13±0.49c |
低海拔高血压组 | 60 | 12.17±3.17a | 158±8a | 105±2a | 7.88±3.90a | 24.64±2.96 | 1.87±0.59a |
低海拔健康组 | 30 | 11.71±3.19 | 122±9 | 84±2 | 0.79±0.37 | 22.17±4.27 | 2.43±0.69 |
F值 | 8.710 | 7.866 | 11.508 | 57.718 | 62.731 | 39.394 | |
P值 | <0.001 | 0.006 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | MTHFR C677T | MTHFR A1298C | MTRR A66G | ||||||
---|---|---|---|---|---|---|---|---|---|---|
CC | CT | TT | AA | AC | CC | AA | AG | GG | ||
高海拔高血压组 | 60 | 41(68.4) | 17(28.3) | 2(3.3) | 30(50.0) | 26(43.3) | 4(6.7) | 26(43.3) | 27(45.0) | 7(11.7) |
低海拔高血压组 | 60 | 15(25.0) | 26(43.3) | 19(31.7) | 32(53.3) | 25(41.7) | 3(5.0) | 36(60.0) | 21(35.0) | 3(5.0) |
χ2值 | 27.717 | 0.227 | 3.963 | |||||||
P值 | <0.001 | 0.893 | 0.138 |
Table 3 Comparison of genotype frequencies among hypertensive subjects across different altitudes
组别 | 例数 | MTHFR C677T | MTHFR A1298C | MTRR A66G | ||||||
---|---|---|---|---|---|---|---|---|---|---|
CC | CT | TT | AA | AC | CC | AA | AG | GG | ||
高海拔高血压组 | 60 | 41(68.4) | 17(28.3) | 2(3.3) | 30(50.0) | 26(43.3) | 4(6.7) | 26(43.3) | 27(45.0) | 7(11.7) |
低海拔高血压组 | 60 | 15(25.0) | 26(43.3) | 19(31.7) | 32(53.3) | 25(41.7) | 3(5.0) | 36(60.0) | 21(35.0) | 3(5.0) |
χ2值 | 27.717 | 0.227 | 3.963 | |||||||
P值 | <0.001 | 0.893 | 0.138 |
组别 | 例数 | MTHFR C677T | MTHFR A1298C | MTRR A66G | ||||||
---|---|---|---|---|---|---|---|---|---|---|
CC | CT | TT | AA | AC | CC | AA | AG | GG | ||
高海拔健康组 | 30 | 14(46.7) | 10(33.3) | 6(20.0) | 19(63.3) | 9(30.0) | 2(6.7) | 17(56.7) | 9(30.0) | 4(13.3) |
低海拔健康组 | 30 | 7(23.3) | 17(56.7) | 6(20.0) | 19(63.3) | 8(26.7) | 3(10.0) | 10(33.4) | 16(53.3) | 4(13.3) |
χ2值 | 4.148 | 0.259 | 3.775 | |||||||
P值 | 0.126 | 0.879 | 0.151 |
Table 4 Comparison of genotype frequencies among healthy subjects across different altitudes
组别 | 例数 | MTHFR C677T | MTHFR A1298C | MTRR A66G | ||||||
---|---|---|---|---|---|---|---|---|---|---|
CC | CT | TT | AA | AC | CC | AA | AG | GG | ||
高海拔健康组 | 30 | 14(46.7) | 10(33.3) | 6(20.0) | 19(63.3) | 9(30.0) | 2(6.7) | 17(56.7) | 9(30.0) | 4(13.3) |
低海拔健康组 | 30 | 7(23.3) | 17(56.7) | 6(20.0) | 19(63.3) | 8(26.7) | 3(10.0) | 10(33.4) | 16(53.3) | 4(13.3) |
χ2值 | 4.148 | 0.259 | 3.775 | |||||||
P值 | 0.126 | 0.879 | 0.151 |
组别 | 例数 | MTHFR C677T | MTHFR A1298C | MTRR A66G | ||||||
---|---|---|---|---|---|---|---|---|---|---|
CC | CT | TT | AA | AC | CC | AA | AG | GG | ||
高海拔高血压组 | ||||||||||
理论值 | 60 | 40.84(68.07) | 17.32(28.87) | 1.84(3.06) | 30.82(51.37) | 24.37(40.61) | 4.81(8.02) | 26.14(43.56) | 26.93(44.88) | 6.93(11.56) |
实际值 | 60 | 41.00(68.34) | 17.00(28.33) | 2.00(3.33) | 30.00(50.00) | 26.00(43.33) | 4.00(6.67) | 26.00(43.33) | 27.00(45.00) | 7.00(11.67) |
χ2值 | 0.02 | 0.27 | 0.01 | |||||||
P值 | 0.99 | 0.87 | 0.99 | |||||||
低海拔高血压组 | ||||||||||
理论值 | 60 | 13.06(21.77) | 29.87(49.78) | 17.07(28.45) | 33.00(55.00) | 22.99(38.32) | 4.01(6.68) | 36.51(60.85) | 20.59(34.32) | 2.90(4.83) |
实际值 | 60 | 15.00(25.00) | 26.00(43.33) | 19.00(31.67) | 32.00(53.33) | 25.00(41.67) | 3.00(5.00) | 36.00(60.00) | 21.00(35.00) | 3.00(5.00) |
χ2值 | 0.01 | 0.46 | 0.02 | |||||||
P值 | 0.60 | 0.80 | 0.99 |
Table 5 Hardy-Weinberg equilibrium analysis of gene polymorphism in hypertensive subjects from different altitude regions
组别 | 例数 | MTHFR C677T | MTHFR A1298C | MTRR A66G | ||||||
---|---|---|---|---|---|---|---|---|---|---|
CC | CT | TT | AA | AC | CC | AA | AG | GG | ||
高海拔高血压组 | ||||||||||
理论值 | 60 | 40.84(68.07) | 17.32(28.87) | 1.84(3.06) | 30.82(51.37) | 24.37(40.61) | 4.81(8.02) | 26.14(43.56) | 26.93(44.88) | 6.93(11.56) |
实际值 | 60 | 41.00(68.34) | 17.00(28.33) | 2.00(3.33) | 30.00(50.00) | 26.00(43.33) | 4.00(6.67) | 26.00(43.33) | 27.00(45.00) | 7.00(11.67) |
χ2值 | 0.02 | 0.27 | 0.01 | |||||||
P值 | 0.99 | 0.87 | 0.99 | |||||||
低海拔高血压组 | ||||||||||
理论值 | 60 | 13.06(21.77) | 29.87(49.78) | 17.07(28.45) | 33.00(55.00) | 22.99(38.32) | 4.01(6.68) | 36.51(60.85) | 20.59(34.32) | 2.90(4.83) |
实际值 | 60 | 15.00(25.00) | 26.00(43.33) | 19.00(31.67) | 32.00(53.33) | 25.00(41.67) | 3.00(5.00) | 36.00(60.00) | 21.00(35.00) | 3.00(5.00) |
χ2值 | 0.01 | 0.46 | 0.02 | |||||||
P值 | 0.60 | 0.80 | 0.99 |
组别 | 例数 | MTHFR C677T | MTHFR A1298C | MTRR A66G | ||||||
---|---|---|---|---|---|---|---|---|---|---|
CC | CT | TT | AA | AC | CC | AA | AG | GG | ||
高海拔健康组 | ||||||||||
理论值 | 30 | 12.03(40.10) | 13.93(46.43) | 4.04(13.47) | 18.41(61.37) | 10.18(33.93) | 1.41(4.70) | 15.41(51.37) | 12.18(40.60) | 2.41(8.03) |
实际值 | 30 | 14.00(46.67) | 10.00(33.33) | 6.00(20.00) | 19.00(63.33) | 9.00(30.00) | 2.00(6.67) | 17.00(56.67) | 9.00(30.00) | 4.00(13.33) |
χ2值 | 2.39 | 0.41 | 2.05 | |||||||
P值 | 0.30 | 0.82 | 0.40 | |||||||
低海拔健康组 | ||||||||||
理论值 | 30 | 8.01(26.70) | 14.98(49.93) | 7.01(23.37) | 17.64(58.80) | 10.73(35.77) | 1.63(5.43) | 10.80(36.00) | 14.40(48.00) | 4.80(16.00) |
实际值 | 30 | 7.00(23.33) | 17.00(56.67) | 6.00(20.00) | 19.00(63.33) | 8.00(26.67) | 3.00(10.00) | 10.00(33.34) | 16.00(53.33) | 4.00(13.33) |
χ2值 | 0.53 | 1.95 | 0.37 | |||||||
P值 | 0.76 | 0.38 | 0.83 |
Table 6 Hardy-Weinberg equilibrium analysis of gene polymorphism in healthy subjects from different altitude regions
组别 | 例数 | MTHFR C677T | MTHFR A1298C | MTRR A66G | ||||||
---|---|---|---|---|---|---|---|---|---|---|
CC | CT | TT | AA | AC | CC | AA | AG | GG | ||
高海拔健康组 | ||||||||||
理论值 | 30 | 12.03(40.10) | 13.93(46.43) | 4.04(13.47) | 18.41(61.37) | 10.18(33.93) | 1.41(4.70) | 15.41(51.37) | 12.18(40.60) | 2.41(8.03) |
实际值 | 30 | 14.00(46.67) | 10.00(33.33) | 6.00(20.00) | 19.00(63.33) | 9.00(30.00) | 2.00(6.67) | 17.00(56.67) | 9.00(30.00) | 4.00(13.33) |
χ2值 | 2.39 | 0.41 | 2.05 | |||||||
P值 | 0.30 | 0.82 | 0.40 | |||||||
低海拔健康组 | ||||||||||
理论值 | 30 | 8.01(26.70) | 14.98(49.93) | 7.01(23.37) | 17.64(58.80) | 10.73(35.77) | 1.63(5.43) | 10.80(36.00) | 14.40(48.00) | 4.80(16.00) |
实际值 | 30 | 7.00(23.33) | 17.00(56.67) | 6.00(20.00) | 19.00(63.33) | 8.00(26.67) | 3.00(10.00) | 10.00(33.34) | 16.00(53.33) | 4.00(13.33) |
χ2值 | 0.53 | 1.95 | 0.37 | |||||||
P值 | 0.76 | 0.38 | 0.83 |
项目 | 例数 | Hcy (μmol/L) | SBP (mmHg) | DBP (mmHg) | GSSG (U/L) | NO (g/mol) | SOD (ng/mL) | HHcy [例(%)] | SBP≥140 mmHg [例(%)] | DBP≥90 mmHg[例(%)] |
---|---|---|---|---|---|---|---|---|---|---|
MTHFR C677T | ||||||||||
CC | 56 | 13.19±3.75a | 168±14a | 107±7 | 10.66±4.64a | 19.28±2.49a | 1.33±0.61a | 18(32.14) | 54(96.43) | 50(89.29) |
CT | 43 | 14.11±2.94 | 171±14 | 108±8 | 7.48±2.79 | 21.58±5.80 | 1.67±0.59 | 16(37.21) | 42(97.67) | 41(95.35) |
TT | 21 | 15.62±1.72a | 174±14a | 105±4 | 6.58±1.54a | 24.25±3.62a | 1.75±0.77a | 12(57.14) | 20(95.24) | 20(95.24) |
F(χ2)值 | 4.519 | 2.889 | 1.530 | 13.995 | 11.675 | 4.954 | 4.074d | 1.105d | 1.564d | |
P值 | 0.013 | 0.040 | 0.221 | <0.001 | <0.001 | 0.009 | 0.130 | 0.576 | 0.458 | |
MTHFR A1298C | ||||||||||
AA | 62 | 12.11±3.44b | 171±14 | 107±6 | 9.08±4.78 | 19.49±5.23 | 1.48±0.75 | 14(22.58)b | 60(96.77) | 59(95.16) |
AC | 51 | 15.11±2.20 | 170±15 | 107±8 | 8.53±3.17 | 20.80±5.10 | 1.56±0.58 | 26(50.98) | 50(98.04) | 46(90.20) |
CC | 7 | 18.17±0.88b | 171±14 | 110±12 | 8.35±1.80 | 21.29±3.90 | 1.55±0.58 | 6(85.71)b | 6(85.71) | 6(85.71) |
F(χ2)值 | 19.437 | 0.355 | 0.770 | 0.312 | 0.561 | 0.195 | 16.607d | 2.906d | 2.030d | |
P值 | <0.001 | 0.702 | 0.465 | 0.733 | 0.572 | 0.823 | <0.001 | 0.234 | 0.362 | |
MTRR A66G | ||||||||||
AA | 62 | 12.37±3.27c | 170±14 | 106±6 | 9.09±2.12 | 18.91±4.39c | 1.33±0.70 | 12(19.35)c | 60(96.77) | 58(93.55) |
AG | 48 | 15.24±2.37 | 173±14 | 107±9 | 8.74±3.36 | 20.14±4.73 | 1.48±0.65 | 25(52.08) | 47(97.92) | 44(91.67) |
GG | 10 | 17.48±1.18c | 164±10 | 110±5 | 8.81±4.72 | 21.96±4.16c | 1.59±0.65 | 9(90.00)c | 9(90.00) | 9(90.00) |
F(χ2)值 | 22.619 | 1.821 | 0.980 | 0.031 | 3.469 | 0.867 | 51.671d | 1.614d | 0.236d | |
P值 | <0.001 | 0.166 | 0.379 | 0.969 | 0.034 | 0.423 | <0.001 | 0.446 | 0.889 |
Table 7 Blood pressure and laboratory test results in hypertensive subjects with different genetic polymorphisms
项目 | 例数 | Hcy (μmol/L) | SBP (mmHg) | DBP (mmHg) | GSSG (U/L) | NO (g/mol) | SOD (ng/mL) | HHcy [例(%)] | SBP≥140 mmHg [例(%)] | DBP≥90 mmHg[例(%)] |
---|---|---|---|---|---|---|---|---|---|---|
MTHFR C677T | ||||||||||
CC | 56 | 13.19±3.75a | 168±14a | 107±7 | 10.66±4.64a | 19.28±2.49a | 1.33±0.61a | 18(32.14) | 54(96.43) | 50(89.29) |
CT | 43 | 14.11±2.94 | 171±14 | 108±8 | 7.48±2.79 | 21.58±5.80 | 1.67±0.59 | 16(37.21) | 42(97.67) | 41(95.35) |
TT | 21 | 15.62±1.72a | 174±14a | 105±4 | 6.58±1.54a | 24.25±3.62a | 1.75±0.77a | 12(57.14) | 20(95.24) | 20(95.24) |
F(χ2)值 | 4.519 | 2.889 | 1.530 | 13.995 | 11.675 | 4.954 | 4.074d | 1.105d | 1.564d | |
P值 | 0.013 | 0.040 | 0.221 | <0.001 | <0.001 | 0.009 | 0.130 | 0.576 | 0.458 | |
MTHFR A1298C | ||||||||||
AA | 62 | 12.11±3.44b | 171±14 | 107±6 | 9.08±4.78 | 19.49±5.23 | 1.48±0.75 | 14(22.58)b | 60(96.77) | 59(95.16) |
AC | 51 | 15.11±2.20 | 170±15 | 107±8 | 8.53±3.17 | 20.80±5.10 | 1.56±0.58 | 26(50.98) | 50(98.04) | 46(90.20) |
CC | 7 | 18.17±0.88b | 171±14 | 110±12 | 8.35±1.80 | 21.29±3.90 | 1.55±0.58 | 6(85.71)b | 6(85.71) | 6(85.71) |
F(χ2)值 | 19.437 | 0.355 | 0.770 | 0.312 | 0.561 | 0.195 | 16.607d | 2.906d | 2.030d | |
P值 | <0.001 | 0.702 | 0.465 | 0.733 | 0.572 | 0.823 | <0.001 | 0.234 | 0.362 | |
MTRR A66G | ||||||||||
AA | 62 | 12.37±3.27c | 170±14 | 106±6 | 9.09±2.12 | 18.91±4.39c | 1.33±0.70 | 12(19.35)c | 60(96.77) | 58(93.55) |
AG | 48 | 15.24±2.37 | 173±14 | 107±9 | 8.74±3.36 | 20.14±4.73 | 1.48±0.65 | 25(52.08) | 47(97.92) | 44(91.67) |
GG | 10 | 17.48±1.18c | 164±10 | 110±5 | 8.81±4.72 | 21.96±4.16c | 1.59±0.65 | 9(90.00)c | 9(90.00) | 9(90.00) |
F(χ2)值 | 22.619 | 1.821 | 0.980 | 0.031 | 3.469 | 0.867 | 51.671d | 1.614d | 0.236d | |
P值 | <0.001 | 0.166 | 0.379 | 0.969 | 0.034 | 0.423 | <0.001 | 0.446 | 0.889 |
项目 | 例数 | SBP(mmHg) | DBP(mmHg) | GSSG(U/L) | NO(g/mol) | SOD(ng/mL) |
---|---|---|---|---|---|---|
非HHcy患者 | 74 | 169±13 | 106±6 | 8.30±4.87 | 22.72±3.44 | 1.64±0.63 |
HHcy患者 | 46 | 172±15 | 109±9 | 9.61±1.82 | 18.18±4.64 | 1.33±0.65 |
t值 | 1.056 | -2.298 | -2.097 | 6.134 | 2.601 | |
P值 | 0.293 | 0.025 | 0.038 | <0.001 | 0.011 |
Table 8 Comparison of blood pressure and laboratory test results between non-HHcy patients and HHcy patients
项目 | 例数 | SBP(mmHg) | DBP(mmHg) | GSSG(U/L) | NO(g/mol) | SOD(ng/mL) |
---|---|---|---|---|---|---|
非HHcy患者 | 74 | 169±13 | 106±6 | 8.30±4.87 | 22.72±3.44 | 1.64±0.63 |
HHcy患者 | 46 | 172±15 | 109±9 | 9.61±1.82 | 18.18±4.64 | 1.33±0.65 |
t值 | 1.056 | -2.298 | -2.097 | 6.134 | 2.601 | |
P值 | 0.293 | 0.025 | 0.038 | <0.001 | 0.011 |
指标 | SBP | DBP | Hcy | GSSG | NO | SOD |
---|---|---|---|---|---|---|
SBP | ||||||
DBP | 0.004 | |||||
Hcy | 0.019 | 0.239a | ||||
GSSG | 0.068 | 0.130 | 0.431a | |||
NO | 0.108 | -0.253a | -0.390a | -0.410a | ||
SOD | -0.070 | -0.074 | -0.253a | -0.400a | 0.526a |
Table 9 Correlation analysis results of blood pressure,homocysteine and oxidative stress indicators in hypertensive subjects
指标 | SBP | DBP | Hcy | GSSG | NO | SOD |
---|---|---|---|---|---|---|
SBP | ||||||
DBP | 0.004 | |||||
Hcy | 0.019 | 0.239a | ||||
GSSG | 0.068 | 0.130 | 0.431a | |||
NO | 0.108 | -0.253a | -0.390a | -0.410a | ||
SOD | -0.070 | -0.074 | -0.253a | -0.400a | 0.526a |
[1] |
|
[2] |
|
[3] |
中国高血压防治指南修订委员会,高血压联盟,中国医疗保健国际交流促进会高血压分会,等. 中国高血压防治指南(2024年修订版)[J]. 中华高血压杂志(中英文),2024,32(7):603-700. DOI:10.16439/j.issn.1673-7245.2024.07.002.
|
[4] |
中国高血压防治指南修订委员会,高血压联盟(中国),中华医学会心血管病学分会中国医师协会高血压专业委员会,等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志,2019,24(1):24-56. DOI:10.3969/j.issn.1007-5410.2019.01.002.
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
格桑平措,熊海,万洋,等. 西藏极高海拔地区藏族血浆同型半胱氨酸水平与MTHFR和MTRR基因多态性的相关性分析[J]. 高原科学研究,2022,6(3):84-91,110. DOI:10.16249/j.cnki.2096-4617.2022.03.011.
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
|
[27] |
|
[28] |
|
[1] | CAO Chenchen, ZHENG Lyuyun, WANG Lin, LIU Jing. Preference Study on Family Doctor Contract Service among Patients with Hypertension and Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2025, 28(16): 2011-2016. |
[2] | CHEN Dian, LONG Huanyu, ZHANG Congxi, CHU Lanhe, LI Shurun, CHEN Yahong. Interpretation of Global Strategy for the Diagnosis, Treatment, Management and Prevention of Chronic Obstructive Pulmonary Disease 2025 Report [J]. Chinese General Practice, 2025, 28(16): 1937-1949. |
[3] | HUANG Zhijie, MAI Zhihua, WANG Haoxiang, HE Yuming, DENG Qiaoyan, DAI Ranran, ZHOU Zhiheng. Multimorbidity of Hypertension, Diabetes, and Dyslipidemia and Influencing Factors of Family Function among the Elderly [J]. Chinese General Practice, 2025, 28(16): 2001-2010. |
[4] | SUI Hongping, LI Tingting, JIANG Tongtong, XIA Yunlong, SHI Tieying. Research Progress on Blood Pressure Management of Vascular Endothelial Growth Factor Signaling Pathway Inhibitor-related Hypertension [J]. Chinese General Practice, 2025, 28(15): 1932-1936. |
[5] | ZHANG Xin, ZHU Qing, LI Nanfang. Association of Lipid Accumulation Product Index and Chronic Kidney Disease in Patients with Hypertension with Abnormal Glucose Metabolism: a Retrospective Cohort Study [J]. Chinese General Practice, 2025, 28(15): 1840-1846. |
[6] | LI Mei, JIANG Dongsheng, ZHAO Jingjing, CAO Yajing, ZHANG Fan, TANG Lijuan, LIU Xiaoli. Correlation Analysis of Homocysteine and Stroke in People over 40 Years Old [J]. Chinese General Practice, 2025, 28(14): 1723-1729. |
[7] | ZHU Jing, XIE Ji, HU Xiaoxia. Study on Anti-inflammatory and Anti-oxidative Stress Mechanism of Sitagliptin: a Dipeptidyl Peptidase-4 Inhibitor [J]. Chinese General Practice, 2025, 28(12): 1543-1548. |
[8] | WANG Jiangtao, DU Yu, ZHU Ling, ZHAO Fouxi, HU Yuandong, LIU Tao. Correlation between Lipid Accumulation Product and the Incidence of Hypertension in Adults: a Prospective Cohort Study [J]. Chinese General Practice, 2025, 28(12): 1433-1438. |
[9] | GU Mingyu, QIN Tingting, QIAO Kun, BAI Xinyuan, WANG Yao, YANG Yutong, LI Xingming. A Network Meta-analysis of Primary Hypertension Management Patterns in China [J]. Chinese General Practice, 2025, 28(10): 1265-1272. |
[10] | ZHOU Yiheng, LYU Yao, YANG Ziyu, YANG Rong, LIU Lidi, ZHANG Peng, DAI Hua, ZENG Rui, WAN Zhi, JIA Yu, LIU Changming, LEI Yi, LIAO Xiaoyang. Interpretation of the Consensus Statement of the British and Irish Hypertension Societies on Adult Hypertension Referral Pathway and Therapeutic Management [J]. Chinese General Practice, 2025, 28(10): 1173-1178. |
[11] | SUN Lin, SHI Yiwei, HOU Xiaomin, GUO Yunting, ZHAO Xu, DONG Lin, NIE Jisheng, QIN Xiaojiang. Relationship between Serum Sodium Levels and Length of Hospital Stay in Patients with Pulmonary Hypertension associated with Left Heart Disease [J]. Chinese General Practice, 2025, 28(09): 1065-1071. |
[12] | Diabetes Prevention and Control Committee of Chinese Preventive Medicine Association. Chinese Diabetes Behavior and Lifestyle Intervention Guidelines (2024) [J]. Chinese General Practice, 2025, 28(07): 777-796. |
[13] | FANG Xiang, SONG Haiqi, LIAO Xiaoyang, LIU Lidi, ZHANG Peng, JIA Yu, YANG Ziyu, YANG Rong, LIU Ruhui. Recommendations for the Management of Hypertensive Disorders of Pregnancy in China: Based on the A Summary of the 2023 Society of Obstetric Medicine of Australia and New Zealand Hypertension in Pregnancy Guideline [J]. Chinese General Practice, 2025, 28(06): 649-654. |
[14] | MA Xiaoyan, CUI Enci, XUE Qun, LIU Rong, ZHANG Xuewu, WANG Qian, WANG Debin, SHEN Xingrong. Study on the Medication Status and Influencing Factors of Hypertensive Patients in the Rural Areas: Based on Family Doctor Contract Services [J]. Chinese General Practice, 2025, 28(03): 365-371. |
[15] | JIANG Shen, WU Jing, ZHOU Jiali, JIANG Denan, SUN Weidi, CHENG Siqing, ZHU Siyu, HOU Leying, SONG Peige. Progress in the Study of the Association between Adverse Childhood Experiences and the Prevalence of Hypertension in Adulthood [J]. Chinese General Practice, 2025, 28(03): 358-364. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||